These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

599 related articles for article (PubMed ID: 24525548)

  • 1. Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice--results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity.
    Flachenecker P; Henze T; Zettl UK
    Eur Neurol; 2014; 71(5-6):271-9. PubMed ID: 24525548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice.
    Flachenecker P; Henze T; Zettl UK
    Eur Neurol; 2014; 72(1-2):95-102. PubMed ID: 24943098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity.
    Koehler J; Feneberg W; Meier M; Pöllmann W
    Int J Neurosci; 2014 Sep; 124(9):652-6. PubMed ID: 24392812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.
    Vermersch P; Trojano M
    Eur Neurol; 2016; 76(5-6):216-226. PubMed ID: 27732980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of physiotherapy intervention on patients with multiple sclerosis-related spasticity treated with nabiximols (THC:CBD oromucosal spray).
    Grimaldi AE; De Giglio L; Haggiag S; Bianco A; Cortese A; Crisafulli SG; Monteleone F; Marfia G; Prosperini L; Galgani S; Mirabella M; Centonze D; Pozzilli C; Castelli L
    PLoS One; 2019; 14(7):e0219670. PubMed ID: 31361750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sativex
    Markovà J; Essner U; Akmaz B; Marinelli M; Trompke C; Lentschat A; Vila C
    Int J Neurosci; 2019 Feb; 129(2):119-128. PubMed ID: 29792372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and Tolerability of THC/CBD Oromucosal Spray for Multiple Sclerosis Spasticity in Italy: First Data from a Large Observational Study.
    Trojano M; Vila C
    Eur Neurol; 2015; 74(3-4):178-85. PubMed ID: 26571097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of nabiximols on Goal Attainment Scale scores in patients with treatment-resistant multiple sclerosis spasticity.
    Paul F; Silván CV
    Neurodegener Dis Manag; 2021 Apr; 11(2):143-153. PubMed ID: 33641348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience.
    D'hooghe M; Willekens B; Delvaux V; D'haeseleer M; Guillaume D; Laureys G; Nagels G; Vanderdonckt P; Van Pesch V; Popescu V
    BMC Neurol; 2021 Jun; 21(1):227. PubMed ID: 34157999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.
    Vermersch P
    Expert Rev Neurother; 2011 Apr; 11(4 Suppl):15-9. PubMed ID: 21449855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of Available Data for the Efficacy and Effectiveness of Nabiximols Oromucosal Spray (Sativex®) in Multiple Sclerosis Patients with Moderate to Severe Spasticity.
    Conte A; Vila Silván C
    Neurodegener Dis; 2021; 21(3-4):55-62. PubMed ID: 34731865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial.
    Meuth SG; Henze T; Essner U; Trompke C; Vila Silván C
    Int J Neurosci; 2020 Dec; 130(12):1199-1205. PubMed ID: 32065006
    [No Abstract]   [Full Text] [Related]  

  • 13. Patient-reported benefits from nabiximols treatment in multiple sclerosis-related spasticity exceed conventional measures.
    Haupts MR; Essner U; Mäurer M
    Neurodegener Dis Manag; 2024 Feb; 14(1):11-20. PubMed ID: 38318862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany.
    Flachenecker P
    Expert Rev Neurother; 2013 Feb; 13(3 Suppl 1):15-9. PubMed ID: 23369055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cortical and spinal excitability in patients with multiple sclerosis and spasticity after oromucosal cannabinoid spray.
    Squintani G; Donato F; Turri M; Deotto L; Teatini F; Moretto G; Erro R
    J Neurol Sci; 2016 Nov; 370():263-268. PubMed ID: 27772772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.
    Syed YY; McKeage K; Scott LJ
    Drugs; 2014 Apr; 74(5):563-78. PubMed ID: 24671907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of nabiximols (Sativex(®)) on multiple sclerosis spasticity in a real-life Italian monocentric study.
    Ferrè L; Nuara A; Pavan G; Radaelli M; Moiola L; Rodegher M; Colombo B; Keller Sarmiento IJ; Martinelli V; Leocani L; Martinelli Boneschi F; Comi G; Esposito F
    Neurol Sci; 2016 Feb; 37(2):235-42. PubMed ID: 26474875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
    Rog DJ; Nurmikko TJ; Young CA
    Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health Authorities Data Collection of THC:CBD Oromucosal Spray (L'Agenzia Italiana del Farmaco Web Registry): Figures after 1.5 Years.
    Patti F
    Eur Neurol; 2016; 75 Suppl 1():9-12. PubMed ID: 26901344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in the management of multiple sclerosis spasticity: recent clinical trials.
    Fernández O
    Eur Neurol; 2014; 72 Suppl 1():9-11. PubMed ID: 25278117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.